{"entity":{"id":"ccdc6","kind":"target","name":"CCDC6","aka":["coiled-coil domain containing 6","Coiled-coil domain-containing protein 6","H4","PTC1","TST1","D10S170"],"tldr":"CCDC6 (Coiled-coil domain-containing protein 6) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target and a tumour suppressor, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Thyroid cancer, Neuroendocrine tumours and 2 more.","summary":"Acts as a structural scaffold that organises free PP2Ac into a configuration that FBXO42 can recognise and ubiquitinate, leading to its proteasomal degradation. Also interacts independently with PPP4C through a mechanism distinct from FBXO42-mediated ubiquitination.\n\nOpen Targets scores its association with cancer at 0.76 (direct and indirect evidence; datatypes clinical 0.97, literature 0.94, genetic association 0.00, somatic mutation 0.82, animal model 0.38). IntOGen calls it a driver in 1 cohort (0 activating, 1 loss-of-function), covering Basal Cell Carcinoma.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:18782","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18782"},{"label":"UniProt Q16204","url":"https://www.uniprot.org/uniprotkb/Q16204/entry"},{"label":"NCBI Gene 8030","url":"https://www.ncbi.nlm.nih.gov/gene/8030"},{"label":"Ensembl ENSG00000108091","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108091"}],"tags":["cancer-genes-wave"],"related":["open-targets","intogen"],"cancers":["lung-cancer","thyroid","neuroendocrine","nsclc","basal-cell-carcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.97; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort. Evidence tier \"approved-drug\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"CCDC6","role":["drug-target","tumour-suppressor"],"evidenceTier":"approved-drug","sources":[{"label":"HGNC HGNC:18782","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18782","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt Q16204","url":"https://www.uniprot.org/uniprotkb/Q16204/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"Open Targets ENSG00000108091","url":"https://platform.opentargets.org/target/ENSG00000108091/associations","note":"association with cancer (MONDO_0004992) 0.76; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.72, thyroid cancer 0.70, neuroendocrine neoplasm 0.63, lung cancer 0.72 (GraphQL API, CC0)"},{"label":"IntOGen CCDC6","url":"https://www.intogen.org/search?gene=CCDC6","note":"driver in 1 cohort (Act 0, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0"}],"hgnc":"HGNC:18782","ensembl":"ENSG00000108091","uniprot":"Q16204","entrez":"8030","biology":"Acts as a structural scaffold that organises free PP2Ac into a configuration that FBXO42 can recognise and ubiquitinate, leading to its proteasomal degradation. Also interacts independently with PPP4C through a mechanism distinct from FBXO42-mediated ubiquitination. Location: Cytoplasm; Cytoplasm, cytoskeleton (UniProt). Locus 10q21.2 (HGNC).","whereFound":["Lung cancer: Open Targets association 0.72 with lung cancer (MONDO_0008903)","Thyroid cancer: Open Targets association 0.70 with thyroid cancer (MONDO_0002108)","Neuroendocrine tumours: Open Targets association 0.63 with neuroendocrine neoplasm (MONDO_0019496)","Non-small-cell lung cancer: Open Targets association 0.72 with non-small cell lung carcinoma (MONDO_0005233)","Basal cell carcinoma: IntOGen driver in 1 cohort (BCC)"],"targetClass":"tumor-suppressor","prevalence":[]},"route":"/targets/ccdc6/","neighbours":{"collection":[{"id":"intogen","kind":"collection","name":"IntOGen","route":"/collections/intogen/"},{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"thyroid","kind":"cancer","name":"Thyroid cancer","route":"/cancers/thyroid/"}]}}